Receptor tyrosine kinase inhibition leads to regression of acral melanoma by targeting the tumor microenvironment.

ABSTRACT:

Background

Acral melanoma (AM) is an aggressive melanoma variant that arises from palmar, plantar, and nail unit melanocytes. Compared to non-acral cutaneous melanoma (CM), AM is biologically distinct, has an equal incidence across genetic ancestries, typically presents in advanced stage disease, is less responsive to therapy, and has an overall worse prognosis.

Methods

An independent analysis of published sequencing data was performed to evaluate the frequency of receptor tyrosine kinase (RTK) ligands and adapter protein gene variants and expression. To target these genetic variants, a zebrafish acral melanoma model and preclinical patient-derived xenograft (PDX) mouse models were treated with a panel of RTK inhibitors. Residual PDX tumors were evaluated for changes in prol

SUBMITTER: Smith EA 

PROVIDER: S-EPMC11613472 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature